{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T14:41:31Z","timestamp":1780929691285,"version":"3.54.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T00:00:00Z","timestamp":1716595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T00:00:00Z","timestamp":1716595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-03066-1","type":"journal-article","created":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T16:01:26Z","timestamp":1716652886000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Analysis of factors influencing target PASI responses and side effects of methotrexate monotherapy in plaque psoriasis: a multicenter study of 1521 patients"],"prefix":"10.1007","volume":"316","author":[{"given":"Funda","family":"Erduran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Emre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y\u0131ld\u0131z","family":"Hayran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esra","family":"Ad\u0131\u015fen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asude Kara","family":"Polat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pelin","family":"\u00dcst\u00fcner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serap","family":"\u00d6zt\u00fcrkcan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perihan","family":"\u00d6zt\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aylin T\u00fcrel","family":"Ermertcan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla Baykal","family":"Sel\u00e7uk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esra Koku","family":"Aksu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u015fe","family":"Akba\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6knur","family":"Kalkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz","family":"Demirseren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selda Pelin","family":"Kartal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep","family":"Topkarc\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arzu","family":"K\u0131l\u0131\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahizer","family":"Yald\u0131z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sema","family":"Aytekin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pelin","family":"H\u0131zl\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheyda","family":"Gharehdaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Borlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00fctfi","family":"I\u015f\u0131k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beng\u00fc Reyhan","family":"Botsal\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eda \u00d6ks\u00fcm","family":"Solak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00fclya","family":"Albayrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melis","family":"G\u00f6n\u00fclal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didem Didar","family":"Balc\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mualla","family":"Polat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munise","family":"Daye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arzu","family":"Ataseven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibel","family":"Y\u0131ld\u0131z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130lkay","family":"\u00d6zer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zge","family":"Zorlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinan","family":"Do\u011fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vefa Asl\u0131","family":"Erdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahar Sevimli","family":"Dikicier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,25]]},"reference":[{"issue":"3S","key":"3066_CR1","first-page":"10","volume":"101","author":"NM Golbari","year":"2018","unstructured":"Golbari NM, Porter ML, Kimball AB (2018) Current guidelines for psoriasis treatment: a work in progress. Cutis 101(3S):10\u201312","journal-title":"Cutis"},{"key":"3066_CR2","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1001\/archderm.1958.01560080060010","volume":"78","author":"WF Edmundson","year":"1958","unstructured":"Edmundson WF, Guy WB (1958) Treatment of psoriasis with folic acid antagonists. AMA Arch Dermatol 78:200\u2013202","journal-title":"AMA Arch Dermatol"},{"issue":"6","key":"3066_CR3","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s13555-023-00930-2","volume":"13","author":"G Damiani","year":"2023","unstructured":"Damiani G, Amerio P, Bardazzi F et al (2023) Real-world experience of methotrexate in the treatment of skin diseases: an Italian Delphi consensus. Dermatol Ther 13(6):1219\u20131241","journal-title":"Dermatol Ther"},{"issue":"5","key":"3066_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13051","volume":"32","author":"EM Attwa","year":"2019","unstructured":"Attwa EM, Elkot RA, Abdelshafey AS, Hafez AR (2019) Subcutaneous methotrexate versus oral form for the treatment and prophylaxis of chronic plaque psoriasis. Dermatol Ther 32(5):e13051","journal-title":"Dermatol Ther"},{"issue":"7","key":"3066_CR5","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.ad.2010.04.002","volume":"101","author":"G Carretero","year":"2010","unstructured":"Carretero G, Puig L, Dehesa L et al (2010) Metotrexato: gu\u00eda de uso en psoriasis [Guidelines on the use of methotrexate in psoriasis]. Actas Dermosifiliogr 101(7):600\u2013613","journal-title":"Actas Dermosifiliogr"},{"issue":"5","key":"3066_CR6","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1586\/1744666X.2015.1026894","volume":"11","author":"O Y\u00e9lamos","year":"2015","unstructured":"Y\u00e9lamos O, Puig L (2015) Systemic methotrexate for the treatment of psoriasis. Expert Rev Clin Immunol 11(5):553\u2013563","journal-title":"Expert Rev Clin Immunol"},{"issue":"8","key":"3066_CR7","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1136\/annrheumdis-2014-205228","volume":"73","author":"MH Schiff","year":"2014","unstructured":"Schiff MH, Jaffe JS, Freundlich B (2014) Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses \u226515 mg may be overcome with subcutaneous administration. Ann Rheum Dis 73(8):1549\u20131551","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"3066_CR8","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1365-2133.2011.10399.x","volume":"165","author":"JH Saurat","year":"2011","unstructured":"Saurat JH, Langley RG, Reich K, Unnebrink K, Sasso EH, Kampman W (2011) Relationship between methotrexate dosing and clinical response in patients with moderate to severe psoriasis: subanalysis of the CHAMPION study. Br J Dermatol 165(2):399\u2013406","journal-title":"Br J Dermatol"},{"issue":"5","key":"3066_CR9","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1111\/j.1365-2133.2011.10615.x","volume":"165","author":"J Barker","year":"2011","unstructured":"Barker J, Hoffmann M, Wozel G et al (2011) Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol 165(5):1109\u20131117","journal-title":"Br J Dermatol"},{"issue":"7","key":"3066_CR10","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1056\/NEJMoa021359","volume":"349","author":"VM Heydendael","year":"2003","unstructured":"Heydendael VM, Spuls PI, Opmeer BC et al (2003) Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 349(7):658\u2013665","journal-title":"N Engl J Med"},{"issue":"1","key":"3066_CR11","first-page":"116","volume":"158","author":"I Flytstr\u00f6m","year":"2008","unstructured":"Flytstr\u00f6m I, Stenberg B, Svensson A, Bergbrant IM (2008) Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. a randomized controlled trial. Br J Dermatol 158(1):116\u2013121","journal-title":"Br J Dermatol"},{"issue":"8","key":"3066_CR12","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1080\/09546634.2022.2117539","volume":"33","author":"AM van Huizen","year":"2022","unstructured":"van Huizen AM, Sikkel R, Caron AGM, Menting SP, Spuls PI (2022) Methotrexate dosing regimen for plaque-type psoriasis: an update of a systematic review. J Dermatolog Treat 33(8):3104\u20133118","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"3066_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/bjd.14816","volume":"175","author":"RB Warren","year":"2016","unstructured":"Warren RB, Weatherhead SC, Smith CH et al (2016) British association of dermatologists\u2019 guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. Br J Dermatol 175(1):23\u201344","journal-title":"Br J Dermatol"},{"issue":"5","key":"3066_CR14","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/ced.15102","volume":"47","author":"C Choonhakarn","year":"2022","unstructured":"Choonhakarn C, Chaowattanapanit S, Julanon N, Limpawattana P (2022) Comparison of the clinical efficacy of subcutaneous vs oral administration of methotrexate in patients with psoriasis vulgaris: a randomized controlled trial. Clin Exp Dermatol 47(5):942\u2013948","journal-title":"Clin Exp Dermatol"},{"issue":"8","key":"3066_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15656","volume":"35","author":"S Dogra","year":"2022","unstructured":"Dogra S, Singh N, Kumar S, Narang T, Handa S (2022) Comparison of overall efficacy and safety of oral versus subcutaneous methotrexate in severe psoriasis. Dermatol Ther 35(8):e15656","journal-title":"Dermatol Ther"},{"issue":"5","key":"3066_CR16","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/jamadermatol.2022.0434","volume":"158","author":"-van Huizen AM, Menting SP, Gyulai","year":"2022","unstructured":"-van Huizen AM, Menting SP, Gyulai R, et al (2022) International eDelphi study to reach consensus on the methotrexate dosing regimen in patients with psoriasis. JAMA Dermatol 158(5):561\u2013572","journal-title":"JAMA Dermatol"},{"issue":"6","key":"3066_CR17","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1111\/j.1365-2133.2006.07289.x","volume":"154","author":"A Salim","year":"2006","unstructured":"Salim A, Tan E, Ilchyshyn A, Berth-Jones J (2006) Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial. Br J Dermatol 154(6):1169\u20131174","journal-title":"Br J Dermatol"},{"issue":"4","key":"3066_CR18","first-page":"219","volume":"63","author":"BL Masuria","year":"1997","unstructured":"Masuria BL, Mittal A, Gupta LK, Sharma M, Bansal N (1997) Methotrexate: side effects and the role of folic acid supplementation in psoriasis\u2014a study. Indian J Dermatol Venereol Leprol 63(4):219\u2013222","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"3","key":"3066_CR19","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/j.1365-2133.2008.08876.x","volume":"160","author":"S Prey","year":"2009","unstructured":"Prey S, Paul C (2009) Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review. Br J Dermatol 160(3):622\u2013628","journal-title":"Br J Dermatol"},{"issue":"3","key":"3066_CR20","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s40257-013-0017-9","volume":"14","author":"A Al-Dabagh","year":"2013","unstructured":"Al-Dabagh A, Davis SA, Kinney MA, Huang K, Feldman SR (2013) The effect of folate supplementation on methotrexate efficacy and toxicity in psoriasis patients and folic acid use by dermatologists in the USA. Am J Clin Dermatol 14(3):155\u2013161","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"3066_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13455","volume":"33","author":"V Lajevardi","year":"2020","unstructured":"Lajevardi V, Kashiri A, Ghiasi M, Khosravi D, Fazlolahi S, Etesami I (2020) Evaluating the efficacy of ursodeoxycholic acid plus methotrexate vs methotrexate alone in the treatment of moderate to severe plaque-type psoriasis: a randomized clinical trial. Dermatol Ther 33(4):e13455","journal-title":"Dermatol Ther"},{"issue":"1","key":"3066_CR22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/ijd.12585","volume":"54","author":"V Lajevardi","year":"2015","unstructured":"Lajevardi V, Hallaji Z, Daklan S, Abedini R, Goodarzi A, Abdolreza M (2015) The efficacy of methotrexate plus pioglitazone vs. methotrexate alone in the management of patients with plaque-type psoriasis: a single-blinded randomized controlled trial. Int J Dermatol 54(1):95\u2013101","journal-title":"Int J Dermatol"},{"issue":"17","key":"3066_CR23","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1056\/NEJMoa1010858","volume":"365","author":"K Reich","year":"2011","unstructured":"Reich K, Langley RG, Papp KA et al (2011) A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med 365(17):1586\u20131596","journal-title":"N Engl J Med"},{"issue":"8","key":"3066_CR24","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1517\/14740338.2014.933805","volume":"13","author":"W Baran","year":"2014","unstructured":"Baran W, Batycka-Baran A, Zychowska M, Bieniek A, Szepietowski JC (2014) Folate supplementation reduces the side effects of methotrexate therapy for psoriasis. Expert Opin Drug Saf 13(8):1015\u20131021","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"3066_CR25","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s00415-004-0287-5","volume":"251","author":"D Renard","year":"2004","unstructured":"Renard D, Westhovens R, Vandenbussche E, Vandenberghe R (2004) Reversible posterior leucoencephalopathy during oral treatment with methotrexate. J Neurol 251(2):226\u2013228","journal-title":"J Neurol"},{"issue":"10","key":"3066_CR26","doi-asserted-by":"publisher","first-page":"3930","DOI":"10.1093\/rheumatology\/keab917","volume":"61","author":"AA Sherbini","year":"2022","unstructured":"Sherbini AA, Gwinnutt JM, Hyrich KL, Co-Investigators RAMS, Verstappen SMM (2022) Rates and predictors of methotrexate-related adverse events in patients with early rheumatoid arthritis: results from a nationwide UK study. Rheumatology 61(10):3930\u20133938","journal-title":"Rheumatology"},{"issue":"9","key":"3066_CR27","doi-asserted-by":"publisher","first-page":"4001","DOI":"10.1093\/rheumatology\/keab304","volume":"60","author":"AA Sherbini","year":"2021","unstructured":"Sherbini AA, Sharma SD, Gwinnutt JM, Hyrich KL, Verstappen SMM (2021) Prevalence and predictors of adverse events with methotrexate mono- and combination-therapy for rheumatoid arthritis: a systematic review. Rheumatology 60(9):4001\u20134017","journal-title":"Rheumatology"},{"issue":"1","key":"3066_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/jcm8010015","volume":"8","author":"A Ibrahim","year":"2018","unstructured":"Ibrahim A, Ahmed M, Conway R, Carey JJ (2018) Risk of infection with methotrexate therapy in inflammatory diseases: a systematic review and meta-analysis. J Clin Med 8(1):15","journal-title":"J Clin Med"},{"issue":"5","key":"3066_CR29","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/ijd.16652","volume":"62","author":"G Caldarola","year":"2023","unstructured":"Caldarola G, De Luca E, Mariani M, Chiricozzi A, Peris K, De Simone C (2023) Drug survival of methotrexate and predictor factors for discontinuation in psoriasis. Int J Dermatol 62(5):649\u2013656","journal-title":"Int J Dermatol"},{"issue":"9","key":"3066_CR30","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1111\/ijd.15628","volume":"60","author":"T Ozkok Akbulut","year":"2021","unstructured":"Ozkok Akbulut T, Topaloglu Demir F, Oguz Topal I et al (2021) Drug survival and predictor factors for discontinuation of methotrexate in psoriasis: a real-life multicenter study. Int J Dermatol 60(9):1140\u20131147","journal-title":"Int J Dermatol"},{"issue":"5","key":"3066_CR31","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1080\/09546634.2016.1273469","volume":"28","author":"C Cabello Zurita","year":"2017","unstructured":"Cabello Zurita C, Grau P\u00e9rez M, Hern\u00e1ndez Fern\u00e1ndez CP et al (2017) Effectiveness and safety of methotrexate in psoriasis: an eight-year experience with 218 patients. J Dermatolog Treat 28(5):401\u2013405","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"3066_CR32","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/j.1365-2133.1994.tb02901.x","volume":"130","author":"RJ Van Dooren-Greebe","year":"1994","unstructured":"Van Dooren-Greebe RJ, Kuijpers AL, Mulder J, De Boo T, Van de Kerkhof PC (1994) Methotrexate revisited: effects of long-term treatment in psoriasis. Br J Dermatol 130(2):204\u2013210","journal-title":"Br J Dermatol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03066-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03066-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03066-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T11:37:36Z","timestamp":1719401856000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03066-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,25]]},"references-count":32,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["3066"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03066-1","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,25]]},"assertion":[{"value":"6 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no conflicts of interest to report relevant to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"278"}}